Valion Bio Inc.
VBIO | NASDAQ
$0.54
-$0.01 (-1.82%)
Nov 2, 2026, 10:14 AM ET · Market open
-1.82%
(1D)No price chart data available for 1D timeframe.
Rating
30
-3.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #801/1028 (Top 78%)
Key Statistics
Market Data
Market Cap $1.12M
1D Range
0.53 0.58
52W Range
0.53 66.50
Valuation (TTM)
PE 0
PB 0.10
EV/EBITDA -1.06
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $0.00
Cash Flow
FCF Yield -1273.1%
SBC Adj. FCF Yield -1316.1%
SBC Impact -3.4%
Margins
Gross Margin 516.0%
Operating Margin 10587.2%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -141.1% |
-52.2%
Dil EPS 3Y | 5Y -22.1% |
78.2%
FCF 3Y | 5Y -57.9% |
-11.5%
Returns
ROA -57.7%
ROE -165.4%
ROIC -55.1%
Financial Health
Net Debt
$5.81M
Current Ratio 1.11
Interest Coverage -12.33
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The compa...
Sector Healthcare
Industry Biotechnology
Employees 52
IPO Date Nov 11, 2021
Website valionbio.com
Fiscal Year April - March
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove VBIO